Filing Flows › Harmony Biosciences Holdings (HRMY) › Q2 2026 › vs Q2 2025
Harmony Biosciences Holdings (HRMY) Q2 2026 vs Q2 2025 (year over year)
Harmony Biosciences Holdings's revenue rose $60.8M (+30%) from $200M in Q2 2025 to $261M in Q2 2026. Gross margin 75.8% against 81.0% (-5.2 pts).
Harmony Biosciences Holdings, Q2 2026: revenue $261M (+30% year over year), operating margin 34.2%, net earnings $75.4M, operating cash flow $92.4M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 75.8% | 81.0% | -5.2 pts |
| Operating margin | 34.2% | 24.0% | +10.2 pts |
| Net margin | 28.9% | 19.8% | +9.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $261M | $200M | $60.8M | +30% |
| Gross profit | $198M | $162M | $35.7M | +22% |
| Cost of revenue | $63.2M | $38.2M | $25.0M | +66% |
| Other income, net | $3.9M | $1.5M | $2.5M | +171% |
| Operating profit | $89.3M | $48.2M | $41.1M | +85% |
| Operating expenses | $109M | $114M | −$5.4M | -5% |
| Pre-tax earnings | $93.3M | $49.6M | $43.6M | +88% |
| Research & development | $46.6M | $50.2M | −$3.6M | -7% |
| Sales & marketing | $34.1M | $30.1M | $4.0M | +13% |
| General & admin | $28.1M | $33.9M | −$5.9M | -17% |
| Net earnings | $75.4M | $39.8M | $35.7M | +90% |
| Income tax | $17.8M | $9.9M | $8.0M | +81% |
| Depreciation & amortization | $6.0M | $6.0M | $1K | 0% |
| Share-based compensation | $9.3M | $11.5M | −$2.1M | -19% |
| Working capital & other | $1.7M | $22.1M | −$20.4M | -92% |
| Operating cash flow | $92.4M | $79.3M | $13.1M | +17% |
Questions
How much did Harmony Biosciences Holdings's revenue grow year over year in Q2 2026?
Harmony Biosciences Holdings's revenue rose $60.8M (+30%) from $200M in Q2 2025 to $261M in Q2 2026. Gross margin 75.8% against 81.0% (-5.2 pts).